Clinical Evaluation of Paclitaxel Liposome Combined with Continuous Intravenous Infusion of Large-Dose 5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIUHua ,  LINGWei , CAOHui

Department of General Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201112, China;

Corresponding author：

LINGWei, Email: lingwei050@163.com

Keywords：

Advanced gastric cancer; Paclitaxel; Liposome; 5-fluorouacil; Chemotherapy

DOI：

10.7507/1007-9424.20140147

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the therapeutic effect and adverse reaction of paclitaxel liposome combined with continuous infusion of large-dose 5-fluorouracil(5-fu) in treatment for advance gastric cancer(AGC). Methods From May 2009 to August 2012, 63 consecutive patients with AGC in this hospital were enrolled in this study. All the patients were given chemotherapy including paclitaxel liposome and continuous infusion of large-dose(2.5 g/m²) 5-fu. The efficacy and toxicity of this regimen were observed. Results There was no patient who could not tolerate adverse reaction related to such regimen. Five cases achieved complete response and 31 cases achieved partial response, the overall response rate was 57.1%(36/63). Hematologic toxicity included gradeⅢ/Ⅳleucopenia 8 cases(12.7%) and neutropenia 10 cases(15.9%), while there was no occurrence of gradeⅢ/Ⅳanemia or thrombopenia. Non-hematologic toxicity was fairly mild. Conclusions Paclitaxel liposome is safe, well tolerated, highly targeted, and has long duration of effect. Paclitaxel liposome combined with continuous infusion of large-dose 5-fu is safe and effective in treatment for patients with AGC.

Citation： LIUHua, LINGWei, CAOHui. Clinical Evaluation of Paclitaxel Liposome Combined with Continuous Intravenous Infusion of Large-Dose 5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(5): 614-617. doi: 10.7507/1007-9424.20140147 Copy

1.	Cervantes A, Roda D, Tarazona N, et al.Current questions for the treatment of advanced gastric cancer[J].Cancer Treat Rev, 2013, 39(1):60-67.
2.	Takeuchi H, Ueda M, Oyama T, et al.Molecular diagnosis and translymphatic chemotherapy targeting sentinel lymph nodes of patients with early gastrointestinal cancers[J].Digestion, 2010, 82(3):187-191.
3.	Sakamoto J, Matsui T, Kodera Y.Paclitaxel chemotherapy for the treatment of gastric cancer[J].Gastric Cancer, 2009, 12(2):69-78.
4.	Scartozzi M, Galizia E, Verdecchia L, et al.Chemotherapy for advanced gastric cancer:across the years for a standard of care[J].Expert Opin Pharmacother, 2007, 8(6):797-808.
5.	Jang GS, Kim MJ, Ha HI, et al.Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer[J].Chin J Cancer Res, 2013, 25(6):689-694.
6.	Su X, Dong C, Zhang J, et al.Combination therapy of anti-cancer bioactive peptide with cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer[J].Cell Biosci, 2014, 4(1):7.
7.	Yamaguchi K, Shimamura T, Ishikubo T, et al.Chemotherapy in advanced gastric cancer-to ensure timely and appropriate switch to subsequent treatment options[J].Gan To Kagaku Ryoho, 2007, 34(1):29-34.
8.	Gotoh M, Kawabe S, Takiuchi H.S-1 combined with weekly paclitaxel in patients with advanced gastric cancer[J].Gan To Kagaku Ryoho, 2006, 33 Suppl 1:91-94.
9.	Kimura Y, Yano H, Imamura H, et al.A phaseⅠstudy of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer[J].Jpn J Clin Oncol, 2013, 43(2):125-131.
10.	Takahashi T, Saikawa Y, Fukuda K, et al.PhaseⅠstudy of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02)[J].Anticancer Res, 2012, 32(12):5401-5406.
11.	Imano M, Yasuda A, Itoh T, et al.PhaseⅡstudy of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis[J].J Gastrointest Surg, 2012, 16(12):2190-2196.
12.	Iwasa S, Goto M, Yasui H, et al.Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake[J].Jpn J Clin Oncol, 2012, 42(9):787-793.
13.	Nishikawa K, Morita S, Matsui T, et al.A randomized phase-Ⅱtrial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer[J].Gastric Cancer, 2012, 15(4):363-369.
14.	Ando T, Hosokawa A, Kajiura S, et al.Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxelbased chemotherapy[J].Gastric Cancer, 2012, 15(4):427-432.
15.	Matsubara J, Shimada Y, Kato K, et al.PhaseⅡstudy of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer[J].Oncology, 2011, 81(5/6):291-297.
16.	Takeyoshi I, Makita F, Iwazaki S, et al.Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites[J].Anticancer Res, 2011, 31(12):4625-4630.
17.	Wang F, Wang Z, Zhou N, et al.PhaseⅡstudy of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer[J].Am J Clin Oncol, 2011, 34(4):401-405.
18.	Li XD, Shen H, Jiang JT, et al.Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer[J].World J Gastroenterol, 2011, 17(8):1082-1087.
19.	Imamoto H, Oba K, Sakamoto J, et al.Assessing clinical benefit response in the treatment of gastric malignant ascites with non-mea surable lesions:a multicenter phaseⅡtrial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer[J].Gastric Cancer, 2011, 14(1):81-90.
20.	Ueda Y, Yamagishi H, Ichikawa D, et al.Multicenter phaseⅡstudy of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer[J].Gastric Cancer, 2010, 13(3):149-154.
21.	Kim JH, Lee KW, Kim YH, et al.Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer[J].J Korean Med Sci, 2010, 25(5):684-690.
22.	Yoshikawa T, Tsuburaya A, Morita S, et al.A comparison of multimodality treatment:two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized phaseⅡtrial (COMPASS)[J].Jpn J Clin Oncol, 2010, 40(4):369-372.
23.	Koizumi W, Akiya T, Sato A, et al.Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer:a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial[J].Jpn J Clin Oncol, 2009, 39(11):713-719.
24.	Kataoka H, Shimura T, Mizoshita T, et al.Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life[J].Hepatogastroenterology, 2009, 56(90):547-550.
25.	Sugimoto N, Narahara H, Sakai D, et al.The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer[J].Gan To Kagaku Ryoho, 2009, 36(3):417-424.

1. Cervantes A, Roda D, Tarazona N, et al.Current questions for the treatment of advanced gastric cancer[J].Cancer Treat Rev, 2013, 39(1):60-67.
2. Takeuchi H, Ueda M, Oyama T, et al.Molecular diagnosis and translymphatic chemotherapy targeting sentinel lymph nodes of patients with early gastrointestinal cancers[J].Digestion, 2010, 82(3):187-191.
3. Sakamoto J, Matsui T, Kodera Y.Paclitaxel chemotherapy for the treatment of gastric cancer[J].Gastric Cancer, 2009, 12(2):69-78.
4. Scartozzi M, Galizia E, Verdecchia L, et al.Chemotherapy for advanced gastric cancer:across the years for a standard of care[J].Expert Opin Pharmacother, 2007, 8(6):797-808.
5. Jang GS, Kim MJ, Ha HI, et al.Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer[J].Chin J Cancer Res, 2013, 25(6):689-694.
6. Su X, Dong C, Zhang J, et al.Combination therapy of anti-cancer bioactive peptide with cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer[J].Cell Biosci, 2014, 4(1):7.
7. Yamaguchi K, Shimamura T, Ishikubo T, et al.Chemotherapy in advanced gastric cancer-to ensure timely and appropriate switch to subsequent treatment options[J].Gan To Kagaku Ryoho, 2007, 34(1):29-34.
8. Gotoh M, Kawabe S, Takiuchi H.S-1 combined with weekly paclitaxel in patients with advanced gastric cancer[J].Gan To Kagaku Ryoho, 2006, 33 Suppl 1:91-94.
9. Kimura Y, Yano H, Imamura H, et al.A phaseⅠstudy of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer[J].Jpn J Clin Oncol, 2013, 43(2):125-131.
10. Takahashi T, Saikawa Y, Fukuda K, et al.PhaseⅠstudy of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02)[J].Anticancer Res, 2012, 32(12):5401-5406.
11. Imano M, Yasuda A, Itoh T, et al.PhaseⅡstudy of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis[J].J Gastrointest Surg, 2012, 16(12):2190-2196.
12. Iwasa S, Goto M, Yasui H, et al.Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake[J].Jpn J Clin Oncol, 2012, 42(9):787-793.
13. Nishikawa K, Morita S, Matsui T, et al.A randomized phase-Ⅱtrial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer[J].Gastric Cancer, 2012, 15(4):363-369.
14. Ando T, Hosokawa A, Kajiura S, et al.Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxelbased chemotherapy[J].Gastric Cancer, 2012, 15(4):427-432.
15. Matsubara J, Shimada Y, Kato K, et al.PhaseⅡstudy of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer[J].Oncology, 2011, 81(5/6):291-297.
16. Takeyoshi I, Makita F, Iwazaki S, et al.Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites[J].Anticancer Res, 2011, 31(12):4625-4630.
17. Wang F, Wang Z, Zhou N, et al.PhaseⅡstudy of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer[J].Am J Clin Oncol, 2011, 34(4):401-405.
18. Li XD, Shen H, Jiang JT, et al.Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer[J].World J Gastroenterol, 2011, 17(8):1082-1087.
19. Imamoto H, Oba K, Sakamoto J, et al.Assessing clinical benefit response in the treatment of gastric malignant ascites with non-mea surable lesions:a multicenter phaseⅡtrial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer[J].Gastric Cancer, 2011, 14(1):81-90.
20. Ueda Y, Yamagishi H, Ichikawa D, et al.Multicenter phaseⅡstudy of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer[J].Gastric Cancer, 2010, 13(3):149-154.
21. Kim JH, Lee KW, Kim YH, et al.Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer[J].J Korean Med Sci, 2010, 25(5):684-690.
22. Yoshikawa T, Tsuburaya A, Morita S, et al.A comparison of multimodality treatment:two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized phaseⅡtrial (COMPASS)[J].Jpn J Clin Oncol, 2010, 40(4):369-372.
23. Koizumi W, Akiya T, Sato A, et al.Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer:a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial[J].Jpn J Clin Oncol, 2009, 39(11):713-719.
24. Kataoka H, Shimura T, Mizoshita T, et al.Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life[J].Hepatogastroenterology, 2009, 56(90):547-550.
25. Sugimoto N, Narahara H, Sakai D, et al.The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer[J].Gan To Kagaku Ryoho, 2009, 36(3):417-424.

Previous Article
Learning Curve of Mitral Valve Replacement through Right Minithoracotomy
Next Article
Learning Curve of Mitral Valve Replacement through Right Minithoracotomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Evaluation of Paclitaxel Liposome Combined with Continuous Intravenous Infusion of Large-Dose 5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content